UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

"Despite the current developments of new treatments in AD, there is a clear need for safe and efficacious oral treatments. Impact on patients' experience of itch and pain along with lesional improvements are key to determine the relevance of a treatment", says Prof. Dr. Eric Simpson. "I am excited to present the results from the Phase 2b ADESOS study at the EADV Congress 2024, showing that orismilast offers the promise as a novel treatment option in AD with early impact on patients' burden of disease, including significant itch reduction from 1 week of treatment."

Denmark, 20/09/2024 (informazione.it - comunicati stampa - salute e benessere)

 says Prof. Dr. Eric Simpson .

, adds Kim Kjøller, Co-CEO of UNION.

Presentation:  Orismilast efficacy in adults with moderate-to-severe atopic dermatitis in a phase 2b trial: early impact on itch and patient-reported outcomes
Session code: D1T01.1
Presenter:  Prof. Dr. Eric Simpson , Professor of Dermatology, School of Medicine, Frances J. Storrs , M.D. Medical Dermatology Professor, Dermatology, School of Medicine
Date and time:  Wednesday September 25, 2024, at 2:30-2:45 PM GMT

Poster title: Molecular effects in the skin of atopic dermatitis after oral treatment with orismilast
ID: 5905
Poster number: P3569
Poster title:  Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a Phase 2b randomized, double-blinded, placebo-controlled clinical trial (ADESOS)
ID: 4256
Poster number:  P0598

Orismilast is a next generation, high potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It acts early in the inflammation cascade, inducing a broad range of anti-inflammatory effects across multiple cytokines involved in many dermatological and immunological diseases.  

UNION is developing orismilast as an oral treatment across immunology. Based on the well-known safety profile of the PDE4 class, initially targeting best-in-class or first-in-class positions in atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis and ulcerative colitis (UC).

The FDA has cleared UNION's Investigational New Drug (IND) application for orismilast and granted Fast Track designation for orismilast for the treatment of moderate to severe AD as well as for the treatment of moderate to severe HS.

Morten Boesen , Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com

Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S
+45 5385 3044
sarah.toft-joergensen@uniontherapeutics.com

UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION's lead asset is orismilast, a next generation, high potency PDE4 B/D inhibitor, for a range of immunological diseases e.g., atopic dermatitis (AD) and hidradenitis suppurativa. Orismilast holds the potential to become the first safe oral treatment in AD. UNION is headquartered in Hellerup, Denmark , and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com  

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-to-present-orismilast-phase-2b-results-in-atopic-dermatitis-as-a-late-breaking-or,c4040268

 

View original content: https://www.prnewswire.co.uk/news-releases/union-therapeutics-to-present-orismilast-phase-2b-results-in-atopic-dermatitis-as-a-late-breaking-oral-presentation-at-the-eadv-congress-2024-302254060.html